The global drug industry shifts from discovery dominance to Chinese licensing leverage
By the time cross-border biotech licensing in greater China reached $137.7 billion last year, the old assumption that Western pharmaceutical groups would discover while Chinese firms manufactured had already collapsed. In oncology labs from Suzhou to Shanghai, the traffic now runs the other direction: patent cliff pressures and R&D cost-cutting are driving Big Pharma toward Chinese-developed drug candidates, while multinational companies increasingly treat China as an integral part of their global R&D infrastructure. The balance of leverage inside the global drug industry has started to migrate upstream, into the chemistry benches and licensing offices of Chinese biotechs.
Pfizer’s latest agreement with Innovent reads less like a conventional licensing transaction than a partial outsourcing of discovery itself. The partnership spans eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs, tied together through a three-tier structure that divides ownership, geography and risk with unusual precision. Innovent will lead development of all 12 programs through Phase 1 trials; Pfizer then assumes global development. For four programs, profits in the United States and Europe will be shared, while Innovent retains rights. Another four hand Pfizer exclusive licenses outside Greater China. The remaining assets give Pfizer exclusive global licenses alongside responsibility for all development costs. Western pharmaceutical groups once bought molecules. They are now buying optionality across entire research portfolios.
That shift has accelerated with startling speed. Chinese drugmakers’ licensing deals more than doubled in 2025, reaching 157 agreements worth $135.7 billion. Chinese pharma companies closed 157 out-licensing deals in 2025, including GeneQuantum’s $13 billion cancer-drug agreement, 3SBio’s oncology licensing deal with Pfizer worth $6 billion, and Hengrui’s $12.5 billion COPD transaction with GSK. The deal sizes themselves are changing the industry’s economics. Average licensing values jumped 76% year over year, while 2026 is already on pace to exceed 2025’s record totals. The beneficiaries are not only venture-backed biotech founders but also multinational companies trying to replace expiring blockbuster revenues without absorbing the full cost of internal research.
Chinese firms strengthened their position by specializing in a part of the pharmaceutical chain where speed and cost discipline matter more than global commercial infrastructure. Macquarie Capital analysts said China retains a strength in chemistry even while lagging in biology, allowing foreign drugmakers to license promising molecules for less than the cost of internal R&D. That cost differential matters more as patent expirations compress margins across global pharma. Industry analysts expect 2026 to surpass another licensing record because the search for externally sourced drug candidates is intensifying, not fading. Every successful licensing agreement reinforces the pricing power of Chinese biotech developers negotiating the next one.
Pfizer has spent decades embedding itself inside China’s healthcare system, long before the current licensing boom turned politically sensitive. The company has operated in China since 1989, maintains a presence in more than 300 Chinese cities, and has built manufacturing facilities, R&D centers and an innovation hub across the country. More than 80 innovative drugs and vaccines have been introduced into China through Pfizer, while the company says it aims to “become an essential part of China healthcare system”. Those investments now provide something more valuable than market access: proximity to the fastest-growing reservoir of externally licensable oncology assets in the world.
Biotech royalties become a macroeconomic buffer for China’s export strategy
The timing collides with a broader restructuring inside the Chinese economy. Weak domestic demand and industrial overcapacity continue to expose China to external risks, particularly through energy volatility and trade protectionism. Yet the global artificial intelligence boom has simultaneously fuelled demand for China-made electronics, supporting advanced manufacturing exports and cushioning growth. The biotech licensing surge adds another export layer, one measured not in containers or semiconductors but in intellectual property royalties, milestone payments and co-commercialisation rights denominated largely outside China.
That export cushion helps explain Beijing’s measured posture toward Washington despite unresolved trade tensions. Donald Trump’s May visit to Beijing produced no major breakthroughs, though both governments agreed to seek reciprocal tariff cuts on at least $30 billion worth of goods. China’s Commerce Ministry publicly urged the United States to honour commitments made under the existing trade truce, particularly to ensure tariff levels do not exceed previously agreed ceilings on Chinese goods. As long as exports remain resilient, China’s economy retains enough insulation to avoid large-scale stimulus, especially after policymakers adopted a softer growth target. Biopharma licensing strengthens that insulation because royalties and milestone payments face fewer logistical choke points than physical exports.
The dependence now cuts both ways. Pfizer’s oncology expansion increasingly relies on Chinese-origin molecules. The Innovent transaction arrives amid Pfizer’s aggressive effort to build its oncology pipeline through Chinese biotech partnerships. Earlier in May, Pfizer announced another major Chinese biotech agreement, this time with 3SBio. Under that arrangement, 3SBio granted Pfizer an exclusive global license outside China for SSGJ-707, a bispecific antibody already in clinical trials for lung, colorectal and gynecological cancers. Initial efficacy and safety data have been promising. Pfizer also secured an option on commercialization rights inside China itself. A company once synonymous with exporting American pharmaceutical innovation increasingly imports its future oncology pipeline from Chinese laboratories.
That dependence creates an awkward inversion for multinational drugmakers betting they can arbitrage Chinese innovation while keeping strategic control elsewhere. The more aggressively Western pharmaceutical groups cut internal R&D costs in favor of licensing Chinese assets, the more pricing leverage migrates to the companies supplying those molecules. Analysts expect China’s early-stage pipeline advantage to persist for at least the next several years. If that timeline holds, balance sheets built around external sourcing absorb rising licensing costs just as Chinese developers accumulate recurring royalty streams and co-commercialisation rights across Western markets. The cost savings that justified the strategy begin eroding precisely because the strategy succeeded.
For Beijing, the significance extends beyond healthcare revenues. Chinese regulators approved 76 innovative drugs in 2025, a pace that signals an industrial policy moving beyond manufacturing scale toward intellectual property ownership. The country that spent decades producing low-margin pharmaceutical ingredients now licenses high-value oncology platforms to the world’s largest drugmakers. In an era when tariffs target steel, batteries and semiconductors, China’s fastest-growing export sector increasingly consists of molecules that exist first as patents, trial data and contractual leverage.
